Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Smith, I. E.
Biganzoli, L.
Cortes-Funes, H.
Stroyakovskiy, D.
Franke, F. A.
Chlistalla, A.
Pierga, J-Y
Thomssen, C.
Pritchard, K.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Hosp Prato, Tuscany Canc Inst, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] City Clin Oncol Hosp, Moscow, Russia
[5] Hosp Caridade Ijui, Ijui, Brazil
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Inst Curie, Paris, France
[8] Univ Halle Wittenberg, Halle, Germany
[9] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：286S / 286S
页数：1
相关论文
共 50 条
  • [41] PHASE 3 STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN PATIENTS (PTS) WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE (ATC)
    Cortes, J.
    Perez, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 43 - 44
  • [42] Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
    Fang, Xuefeng
    Zhong, Chenhan
    Weng, Shanshan
    Hu, Hanguang
    Wang, Jian
    Xiao, Qian
    Wang, Jianwei
    Sun, Lifeng
    Xu, Dong
    Liao, Xiujun
    Dong, Caixia
    Zhang, Suzhan
    Li, Jun
    Ding, Kefeng
    Yuan, Ying
    BMC CANCER, 2023, 23 (01)
  • [43] Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
    Xuefeng Fang
    Chenhan Zhong
    Shanshan Weng
    Hanguang Hu
    Jian Wang
    Qian Xiao
    Jianwei Wang
    Lifeng Sun
    Dong Xu
    Xiujun Liao
    Caixia Dong
    Suzhan Zhang
    Jun Li
    Kefeng Ding
    Ying Yuan
    BMC Cancer, 23
  • [44] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study
    Peng, Peijian
    Xu, Xiaolu
    Zhong, Jincai
    Ye, Jin-Hui
    Wang, Zhi-Hui
    Wang, Hong
    Lin, Hong
    Du, Caiwen
    Zou, Guorong
    Ouyang, Jie
    Shi, Ying-ying
    Xu, Fei
    Yu, Gengsheng
    Lu, Yongkui
    Wang, Yong-Xia
    Cui, Shi-En
    Li, Lu-Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Lupi, Cristiana
    Sensi, Elisa
    Lonardi, Sara
    Mezi, Silvia
    Tomasello, Gianluca
    Ronzoni, Monica
    Zaniboni, Alberto
    Tonini, Giuseppe
    Carlomagno, Chiara
    Allegrini, Giacomo
    Chiara, Silvana
    D'Amico, Mauro
    Granetto, Cristina
    Cazzaniga, Marina
    Boni, Luca
    Fontanini, Gabriella
    Falcone, Alfredo
    LANCET ONCOLOGY, 2015, 16 (13): : 1306 - 1315
  • [46] A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer
    Schoffski, P.
    De Benedictis, E.
    Gendreau, S.
    Gianni, L.
    Krop, I.
    Levy, G.
    Ware, J.
    Wildiers, H.
    Winer, E. P.
    CANCER RESEARCH, 2011, 71
  • [47] Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study
    Cortes, Javier
    Awada, Ahmad
    Kaufman, Peter Andrew
    Yelle, Louise
    Perez, Edith A.
    Velikova, Galina
    Wanders, Jantien
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina
    Simons, W. Robert
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] A Phase 1b, Open-Label Study to Evaluate the Safety of Ganitumab (AMG 479) in Combination With Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
    Ikeda, M.
    Okusaka, T.
    Fukutomi, A.
    Otani, S.
    Shibayama, K.
    Takubo, T.
    Gansert, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S467 - S467
  • [49] A phase II, open-label, multicenter, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance therapy as first-line treatment for metastatic or recurrent gastric cancer
    Shen, L.
    Gong, J.
    Zhang, X.
    Hu, B.
    Zhang, F.
    Zhang, J.
    Xu, N.
    Fan, Q.
    Bai, Y.
    Jiao, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [50] A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.
    Xiao, J.
    Zhang, Y.
    Yuan, X.
    He, M.
    Fang, W.
    Zhang, Y.
    Wang, W.
    Hu, X.
    Ma, Z.
    Yao, Y.
    Zhuang, Z.
    Zhou, F.
    Ying, J.
    Yuan, Y.
    Zou, Q.
    Guo, Z.
    Wu, X.
    Jin, Y.
    Mai, Z.
    Guo, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S364 - S364
12345